Authors
Yuliya V Perfilyeva, Nurshat Abdolla, Aikyn Kali, Raikhan Tleulieva, Anastassiya V Perfilyeva, Yuriy A Skiba, Yekaterina O Ostapchuk
Published in
Future oncology (London, England). Pages 1-13. Oct 13, 2026. Epub Oct 13, 2026.
Abstract
Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis.
A systematic literature search was conducted in PubMed, Web of Science, Scopus, and ClinicalTrials.gov from database inception to 27 July 2026. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).
Thirteen studies comprising 1,504 patients were included. Elevated baseline IL-6 was significantly associated with worse OS (hazard ratio [HR] = 2.29, 95%, confidence interval [CI]: 1.87-2.81; p < 0.001), PFS (HR = 1.70, 95% CI: 1.39-2.07; p < 0.001), ORR (odds ratio [OR] = 0.37, 95% CI: 0.23-0.59; p < 0.001), and DCR (OR = 0.39, 95% CI: 0.19-0.78; p = 0.008). Evidence regarding the prognostic value of on-treatment IL-6 concentrations and longitudinal changes during therapy was limited and heterogeneous.
High baseline IL-6 is associated with poor prognosis and reduced treatment response in HCC patients receiving systemic therapy, warranting further treatment-specific evaluation of its prognostic utility.
www.crd.york.ac.uk/prospero identifier is CRD420261456976.
PMID:
42870428
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0